Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma: a Prospecitve, Parallel, Multicenter, Phase III, Randomized Clinical Trial
Sponsor: First Affiliated Hospital, Sun Yat-Sen University
A PHASE3 clinical study on Nasopharyngeal Carcinoma and PD-1, this trial is actively recruiting participants. The trial is conducted by First Affiliated Hospital, Sun Yat-Sen University and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2021 — Jul 2023 [monthly]
Recruiting PHASE3
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital, Sun Yat-Sen University
- First People's Hospital of Foshan
- Nanfang Hospital, Southern Medical University
- Sun Yat-sen University
- Tenth Affiliated Hospital, Sun Yat-sen University
- Zhongshan People's Hospital, Guangdong, China
For direct contact, visit the study record on ClinicalTrials.gov .